Use of Mitoxantrone Hydrochloride Liposomes
JP2025523701A5Pending Publication Date: 2026-07-24CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO LTD
- Filing Date
- 2023-07-19
- Publication Date
- 2026-07-24
AI Technical Summary
Technical Problem
Current treatments for neuromyelitis optica spectrum disorder (NMOSD) are inadequate in effectively managing high recurrence and disability, with existing drugs like mitoxantrone hydrochloride posing significant cardiotoxic risks, and dosage requirements vary based on individual patient conditions.
Method used
The use of mitoxantrone hydrochloride liposomes, formulated with specific particle sizes and phospholipid compositions, administered intravenously every 12 weeks, to treat NMOSD, even after failure of other treatments.
Benefits of technology
Mitoxantrone hydrochloride liposomes demonstrate safety, tolerability, and improved therapeutic efficacy with reduced cardiotoxicity, effectively inhibiting AQP4 deletion and delaying NMOSD recurrence.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 00000000_0000_ABST
Abstract
The present invention provides the use of mitoxantrone hydrochloride liposomes for treating neuromyelitis optica spectrum disorder, and also provides a method for treating an individual's neuromyelitis optica spectrum disorder, the method comprising administering to the individual a therapeutically effective amount of mitoxantrone hydrochloride liposomes or a pharmaceutical composition comprising mitoxantrone hydrochloride liposomes. The results of animal tests and clinical trials have shown that mitoxantrone hydrochloride liposomes are safe and effective against neuromyelitis optica spectrum disorder.
Need to check novelty before this filing date? Find Prior Art